CRYSVITA is de eerste goedgekeurde biologische behandeling in de EU voor patiënten met TIO die geen chirurgische verwijdering van tumoren kunnen ondergaan
TOKYO, Japan–(BUSINESS WIRE)– Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) heeft vandaag aangekondigd dat de Europese Commissie (EC) CRYSVITA® (burosumab) heeft goedgekeurd voor de behandeling van FGF23-gerelateerde hypofosfatemie bij tumor- Geïnduceerde osteomalacie (TIO) geassocieerd met fosfaturische mesenchymale tumoren (PMT’s) die niet curatief kunnen worden verwijderd of gelokaliseerd bij kinderen en adolescenten van 1 tot 17 jaar en bij volwassenen.1 CRYSVITA is ook al goedgekeurd in de EU voor gebruik bij de zeldzame ziekte X- Gekoppelde hypofosfatemie (XLH), voor kinderen en adolescenten tussen 1 en 17 jaar met radiografisch bewijs van botziekte, en bij volwassenen.2
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
CRYSVITA is the first approved biologic treatment in the EU for patients with TIO who cannot undergo surgical removal of tumours
TOKYO, Japan–(BUSINESS WIRE)– Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2
Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detrimental impact on ability to perform daily activities, as well as on physical and social wellbeing.8
A cure for TIO can be achieved with complete surgical resection of the causative tumour(s), however, surgical resection is not always possible due to the anatomical location and difficulty in detecting tumours.3,5 TIO may recur and persist following incomplete or unsuccessful surgical resection.9
With this approval by the European Commission, CRYSVITA is the first biologic treatment available to EU patients within its licensed indication for TIO. CRYSVITA blocks the action of fibroblast growth factor-23 (FGF23), which is produced in excess in TIO, restoring phosphate homeostasis.2,10
“The approval by the European Commission is a very welcome milestone for those living with TIO that cannot be cured by complete surgical resection,” said Professor Ralf Oheim, Department of Osteology and Biomechanics, University Medical Center Hamburg. “With the challenges faced by those living with TIO and those treating it, the unmet need in TIO has been clear for a long time and today’s decision will help support those living with TIO and those healthcare professionals supporting them address such unmet need.”
“This is a momentous day for the TIO community in Europe and I’m proud that Kyowa Kirin can be a part of meeting the needs of people who have such a high unmet need”, said Abdul Mullick, President of Kyowa Kirin International. “Our purpose is to make people smile, and with this new indication for a rare disease with limited available treatment options, we can truly say that together with the TIO community, we are living our purpose.”
With this EC approval, Kyowa Kirin International will work with local health authorities in each country under the purview of the EC to ensure that those living with TIO are able to gain access to CRYSVITA as soon as possible.
▼This medicinal product is subject to additional monitoring.
About Tumour-Induced Osteomalacia (TIO)
TIO is characterised by chronic hypophosphataemia caused by tumour(s) secreting excess fibroblast growth factor 23 (FGF23),3 which can lead to issues such as decreased intestinal absorption of phosphate and compromised vitamin D activation.3,4
The most common signs and symptoms include bone pain, difficulty walking, pathological fractures, height loss and muscle weakness.6 In TIO, muscle weakness and pain severely interfere with physical functioning, including standing up without assistance, walking and ability to work.8 The pain in TIO also severely interferes with mood and moderately interferes with enjoyment of life for those living with it.8
TIO diagnosis is often missed and/or delayed and testing serum phosphate levels is important for diagnosis.3 The only cure in TIO is complete removal of the causative tumour(s).3 Pharmacological treatment should be considered in TIO cases where tumour(s) cannot be curatively resected or localised.3 Restoring phosphate homeostasis is essential to improve the health of people living with TIO.3
About CRYSVITA® (burosumab) in TIO
CRYSVITA (burosumab) was created and developed by Kyowa Kirin and is a recombinant fully human monoclonal antibody that binds to and inhibits the activity of FGF23.2 CRYSVITA blocks the action of FGF23, which is produced in excess in TIO, restoring phosphate homeostasis.2
The efficacy and safety of CRYSVITA have been demonstrated in two Phase 2 clinical trials published in the disease area of TIO.11,12 CRYSVITA was well-tolerated and demonstrated an acceptable safety profile.11,12
Following this new EC approval, CRYSVITA is now indicated in the EU for the treatment of FGF23-related hypophosphataemia in TIO associated with PMTs that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults1, as well as for XLH in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.2 CRYSVITA is given as a subcutaneous injection, every 4 weeks in adults and every 2 weeks in children and adolescents aged 1 to 17 years.2
CRYSVITA is currently approved for use in the treatment of TIO in a number of countries, including the United States13 and Japan.14
Kyowa Kirin and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) have been collaborating in the development and commercialisation of CRYSVITA globally, based on the collaboration and licence agreement between Kyowa Kirin and Ultragenyx.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan based global specialty pharmaceutical company with a heritage of more than 70 years, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas such as nephrology, oncology, immunology/allergy and neurology. Across its four regions – Japan, Asia Pacific, North America and EMEA/International – Kyowa Kirin focuses on its purpose, to make people smile, and is united by its shared values of commitment to life, teamwork, innovation and integrity.
You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/
Kyowa Kirin International
Galabank Business Park
Galashiels, TD1 1QH
1 European Commission. Union Register of Medicinal Products for Human Use. CRYSVITA. 2022. Available at: https://ec.europa.eu/health/documents/community-register/html/h1262.htm. Last Accessed: August 2022.
2 Kyowa Kirin Limited. CRYSVITA (burosumab). Summary of Product Characteristics. 2021.
3 Brandi ML, et al. Challenges in the management of tumor-induced osteomalacia (TIO). Bone. 2021;152:1160-64.
4 Florenzano P, et al. Tumor-Induced Osteomalacia. Calcified Tissue International. 2021;108:128-42.
5 Dahir K, et al. Diagnosis and Management of Tumor-Induced Osteomalacia: Perspectives from Clinical Experience. Journal of the Endocrine Society. 2021;5:1-12.
6 Feng J, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocrine Journal. 2017;64:675-83.
7 Minisola S, et al. Tumour-induced osteomalacia. Nature Reviews Disease Primers. 2017 ;3 :17044.
8 Jerkovich F, et al. Burden of Disease in Patients with Tumor-Induced Osteomalacia. JBMR Plus. 2020;5:e10436.
9 Cianferotti L, et al. Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series. Endocrine. 2022;76:709-721.
10 Oe Y, et al. Medicine (Baltimore). 2021;100:e27895.
11 Imanishi Y, et al. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients with Tumor-Induced Osteomalacia. Journal of Bone and Mineral Research. 2021;36:262-70.
12 Jan de Beur S, et al. Burosumab for the Treatment of Tumor-Induced Osteomalacia. Journal of Bone and Mineral Research. 2021;36:627-35.
13 Kyowa Kirin. Ultragenyx and Kyowa Kirin Announce US FDA Approval of CRYSVITA (Burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO). 2020. Available at: https://www.kyowakirin.com/media_center/news_releases/2020/pdf/e20200619_01.pdf. Last Accessed: August 2022.
14 Kyowa Kirin. Kyowa Kirin Announces Approval of CRYSVITA (Burosumab) for the Treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia in Japan. Available at: https://www.kyowakirin.com/media_center/news_releases/2019/e20190920_01.html. Last Accessed: August 2022.
Date of preparation: August 2022
Contacts for Kyowa Kirin Co., Ltd.:
Contacts for Kyowa Kirin International:
+44 (0) 7769 656073
Email: Stacey.Minton@kyowakirin.comCheck out our twitter: @NewsNovumpr